[Dec-2023] RAPS RAC-US Dumps – Reduce Your Chance of Failure in RAC-US Exam
To help you achieve your ultimate goal, we suggest the actual RAPS RAC-US dumps for your Regulatory Affairs Certification (RAC) US exam preparation to use as your guideline.
NEW QUESTION # 24
The requirements for document control are located in which of the following documents?
- A. ISO 13485
- B. IEC 60601
- C. ICH guidelines
- D. WHO guidelines
Answer: A
NEW QUESTION # 25
One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority's request?
- A. "We have no additional information to provide at this time because we have already provided everything needed to support our product's approval."
- B. "We disagree with the advisory committee's decision because the committee neglected the thorough safety analysis that we provided."
- C. "We have no additional information to provide at this time, but we can perform an additional analysis for a specific safety concern, if necessary."
- D. "Given the advisory committee's unanimous decision, we know that the product will not be approved, and additional data will not make any difference."
Answer: C
NEW QUESTION # 26
During several monitoring visits, a clinical trial monitor identifies serious and repeated noncompliance on the part of the PI. What action should the sponsor take?
- A. Inform the institution that granted a medical license to the Pi.
- B. Send a letter of complaint to the Ethics Committee that approved the site.
- C. Terminate the PI and inform the regulatory authorities.
- D. Increase the frequency of monitoring visits.
Answer: C
NEW QUESTION # 27
Which of the following statements regarding export regulations for an approved product is CORRECT?
- A. The product must not be sold or offered for sale in domestic commerce.
- B. The product must not be in conflict with the laws of the country to which it is intended for export.
- C. The product must not be in accord with the specifications of the foreign purchaser.
- D. The product must not be labeled on the outside of the shipping package that it is intended for export.
Answer: B
NEW QUESTION # 28
The safety database for an anti-hypertensive drug consists of the following:
* 461 patients exposed for three months
* 343 patients exposed for six months
* 112 patients exposed for nine months
* 74 patients exposed for 12 months
Overall exposure is 2.000 patients. Which long-term ICH data requirement has NOT been met?
- A. 500 patients for three months
- B. 200 patients for nine months
- C. 3.000 total patient exposures
- D. 100 patients for 12 months
Answer: D
NEW QUESTION # 29
After numerous failed attempts to decrease an identified risk in a medical device to an acceptable level, the medical device continues to have unacceptable risks. However, the development team wants to continue development. Which is the BEST recommendation to make in this situation?
- A. Redesign the device.
- B. Discontinue the project.
- C. Perform another risk-benefit analysis.
- D. Add a warning in the IFU.
Answer: A
NEW QUESTION # 30
Which of the following claims would classify an apple as a drug?
- A. "It will make you look younger."
- B. "It will whiten teeth."
- C. "It will prevent colds."
- D. "It will satisfy hunger."
Answer: C
NEW QUESTION # 31
As part of the regulatory strategy for companies intending to manufacture a psychotropic product, which of the following approvals should be received FIRST?
- A. Product license
- B. Import license
- C. Site license
- D. Export license
Answer: C
NEW QUESTION # 32
As a member of the product launch review committee, a regulatory affairs professional discovers a major issue with the labeling of a product prior to production. In addition to informing the committee, which is the BEST approach to address the issue?
- A. Delay the start of product production.
- B. Inform the regulatory authorities.
- C. Abort the product launch.
- D. Correct the label text.
Answer: B
NEW QUESTION # 33
Company X encounters challenges in the global life cycle management of its medical devices. Which of the following Is MOST appropriate for improving product life cycle management?
- A. Utilize the STED template to complete global requirements.
- B. Initiate a global submission process after all submission data are finalized.
- C. Plan regulatory approval update meetings with senior management and stakeholders.
- D. Identify countries where special requirements exist during the product development phase.
Answer: D
NEW QUESTION # 34
Which of the following is the BEST approach for mitigating potential regulatory compliance issues at your company?
- A. Develop documented procedures for regulatory compliance processes and train personnel.
- B. Train all new employees on regulatory compliance processes and assign a mentor to them.
- C. Train employees on all regulatory compliance processes using state-of-the-art systems.
- D. Document any failure to follow regulatory compliance processes in employee performance reviews.
Answer: A
NEW QUESTION # 35
In addition to protection, what parameters MUST be considered when selecting the primary package (or a product?
- A. Efficacy and material
- B. Volume and material
- C. Compatibility and safety
- D. Safety and efficacy
Answer: C
NEW QUESTION # 36
Which of the following changes to a drug product is MOST likely to be implemented without prior regulatory authority approval?
- A. Deleting an ingredient of the drug product
- B. Introducing a new analytical method
- C. Strengthening a precaution to the product labeling
- D. Deleting a drug substance
Answer: C
NEW QUESTION # 37
A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?
- A. Product release and validation
- B. Early technical design and product release
- C. Concept development and validation
- D. Concept development and early technical design
Answer: D
NEW QUESTION # 38
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
- A. Subject is hospitalized for the purpose of product administration.
- B. Subject's hospitalization is prolonged during the clinical trial.
- C. Subject is hospitalized due to complications of the product administration.
- D. Subject's hospitalization is due to an unscheduled hip operation.
Answer: A
NEW QUESTION # 39
During an audit of a contract manufacturing facility by a potential client, the auditor requested to be left alone in the records room. The records room contains information on all products produced by the contract manufacturer.
Which action is MOST appropriate for the regulatory affairs professional to take?
- A. Deny the auditor access to the room and records due to confidentiality concerns.
- B. Allow the auditor accompanied access to the room to retrieve the records.
- C. Allow the auditor access to the room and records due to the current audit.
- D. Deny the auditor access to the room and retrieve only the requested records.
Answer: B
NEW QUESTION # 40
A company's product was approved by a regulatory authority with the condition that further studies must be completed prior to full approval of the product.
To minimize product-associated risk to patients during the period of conditional approval, what is the LEAST effective way to achieve this goal?
- A. Delay product launch until required studies are completed.
- B. Educate patients and healthcare providers on how to use the product
- C. Promote off-label use to a carefully selected patient population.
- D. Label the product for use in appropriate populations.
Answer: C
NEW QUESTION # 41
Which of the following double-blind clinical trial designs would be MOST appropriate for a
Phase III study with a new product intended to treat an acute life-threatening disease with less than optimal available therapy?
- A. Placebo-controlled
- B. Dose-ranging
- C. Active-controlled
- D. Cross-over
Answer: D
NEW QUESTION # 42
The API used for an approved drug product conforms to international monograph specifications and local pharmacopeia; however, the international monograph specifications of the API will be changing soon. Which is the most appropriate action for the regulatory affairs professional to take FIRST?
- A. Confirm that the international monograph change is not related to local pharmacopeia.
- B. Prepare the international monograph change submission first and then prepare the local change when required.
- C. Analyze the impact of the international monograph change on the local pharmacopeia.
- D. Transfer the notice of the upcoming international monograph change to QA for further processing.
Answer: D
NEW QUESTION # 43
......
Accurate & Verified Answers As Seen in the Real Exam here: https://examsboost.actual4dumps.com/RAC-US-study-material.html